Sun Pharma Advanced Research Company share news and announcements
NSE: SPARCBSE: 532872Pharmaceuticals & BiotechnologySmall Cap
Last close ₹171.77down ₹1.32 (0.76%)BSE ₹171.75
Share price at the NSE close on 23 Oct 2026. Previous close ₹173.09.
52-week range of traded prices to 23 Oct 2026
₹108.00Low, 23 Mar 2026₹289.00High, 8 Jul 2026
- Next results date: the board meets on 2 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹5,574 Cr778th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 3.5
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 18 May 2026
- 4.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 10 Aug 2026
- 118.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 84.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 18 May 2026
- 0.42
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 7,97,11238.6% delivered
Sun Pharma Advanced Research Company share news and announcements
583 announcements, routine notices left out, newest first. Page 11 of 12.
Dec 2012
Oct 2012
16 Oct · Board meeting
Interalia, to consider and take on record the Unaudited Financial Results of the Company for the second quarter ended September 30, 2012.4 Oct · Business
Pursuant the Rights Issue of Equity Shares of the Company, 29588056 Equity Shares of the Company of Re.1 each, partly paid upto the extent of Re. 0.60/- are to be issued and allotted to 13067 allotees who have applied for Equity Shares of the Company. Accordingly, the Fund Mobilising Committee of the Company at its meeting held on October 03, 2012 has allotted 29,588,056 (Two Crore Ninety Five Lac Eighty Eight Thousand and Fifty Six) Equity Shares of Re.1/- each, partly paid upto the extent of Re.0.60/- bearing Distinctive Nos From 207116392 to 236704447 to the 13067 allotees who have applied for Equity Shares of the Company Consequently, the paid up Equity Share Capital of the Company has increased from Rs.207116391 to Rs.224869224.60 as of date.
Sep 2012
18 Sep · Updates
In terms of the Letter of Offer and the applicable provisions of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009, the Funds Mobilising Committee of the Company on September 17, 2012, vide circular resolution has decided to extend the Issue Period by one working day taking into consideration the proposed nation-wide bandh called by certain parties. The Issue was scheduled to close on September 20, 2012, and the Issue Period has been extended by one working day and the Issue would consequently close on September 21, 2012. All other terms and conditions prescribed in the Letter of Offer, shall Continue to be applicable.
Aug 2012
10 Aug · Corporate action
Funds Mobilising Committee has also fixed the Book Closure Period from August 25, 2012 to August 27, 2012 (both days inclusive) for the purpose of the Rights Issue.
Jul 2012
20 Jul · Board meeting
Interalia, to consider and take on record the Un-audited Financial Results of the Company for the first quarter ended June 30, 2012.
May 2012
Apr 2012
17 Apr · Board meeting
Interalia, to consider and approve the Audited Financial Results of the Company for the year ended March 31, 2012.
Feb 2012
Jan 2012
19 Jan · Board meeting
Interalia, to consider and take on record the Unaudited Financial Results of the Company for the third quarter ended December 31, 2011.
Oct 2011
12 Oct · Board meeting
Interalia, to consider and take on record the Financial Results of the Company for the second quarter/ half year ended September 30, 2011.
Sep 2011
Aug 2011
Jul 2011
29 Jul · Board meeting
Interalia, to consider and take on record the Un-audited Financial Results of the Company for the first quarter ended June 30, 2011.14 Jul · Board meeting
Committee of the Board of Directors has, vide its resolution passed in the meeting held on July 14, 2011 authorized the further issuance of equity shares of Re. 1 each of the Company, on rights basis to the shareholders of the Company on such ratio and at such price and premium as may be decided in consultation with the Lead Managers to the proposed rights issue, so that the funds raised by way of right issue of shares is not more than Rs.200 crores. The ratio of rights share entitlements, the issue price and the record date for fixing the entitlement of shareholders to such rights issue shall be informed in due course when decided.11 Jul · Board meeting
To consider in principle, the issue of equity shares of Re.1 each of the Company by way of rights issue for raising the funds for the Company. Further the Company has informed the Exchange that as per the agenda of the Committee Meeting, however the Committee shall not decide at the said meeting about the ratio of rights share entitlements, the issue price and the record date for fixing the rights entitlement of shareholders & which shall be decided in due course .7 Jul · Meeting
Register of Members and Share Transfer Books of the Company will be closed from August 01, 2011 to August 08, 2011 (both days inclusive) for the purpose of holding Annual General Meeting of the Company to be held on August 08, 2011.
Jun 2011
May 2011
Apr 2011
26 Apr · Board meeting
Interalia, to consider and approve the Audited Financial Results of the Company for the year ended March 31, 2011.
Feb 2011
Jan 2011
18 Jan · Board meeting
Interalia, to consider and take on record the Un-audited Financial Results of the Company for the third quarter / nine months ended December 31, 2010.
Oct 2010
12 Oct · Board meeting
Interalia, to consider and take on record the Un-audited Financial Results of the Company for the second quarter ended September 30, 2010.
Jul 2010
9 Jul · Board meeting
Interalia, to consider and take on record the Un-audited Financial Results of the Company for the first quarter ended June 30, 2010.
Jun 2010
22 Jun · Meeting
Register of Members and Share Transfer Books of the Company will be closed from July 20, 2010 to July 24, 2010 (both days inclusive) for the purpose of holding of Annual General Meeting of the Company to be held on July 24, 2010.
May 2010